MedTrace Logo

Kidney Cancer

Disease

Disease Profile

Kidney cancer, also called renal cancer, is cancer that starts in kidney cells, most commonly renal cell carcinoma. It may invade nearby tissues and spread to distant organs if not detected and treated early.

Category
malignant neoplasm
Prevalence
In the U.S. (2026 estimates), about 80,450 new kidney cancer cases are expected, and lifetime risk is about 1 in 45 for men and 1 in 75 for women.

Related News

Multiple Studies Link Accelerated Biological Aging to Rising Early-Onset Cancer in Younger Generations

Two studies published in Nature Medicine and Military Medical Research link accelerated biological aging in younger generations to rising rates of early-onset cancers. Researchers found that people born in more recent decades show larger gaps between their chronological and biological ages, with stronger risks for lung, gastrointestinal, and uterine cancers. A separate global analysis identified six cancers now rising faster in younger adults than older populations.

Oncology Pipeline Update: Prostate Cancer T-Cell Engager Partnership, BTK Inhibitor Filing, and Novel Targeted Therapy Results

Key oncology developments include a $315 million partnership between Astellas and Vir for the prostate cancer T-cell engager VIR-5500, with updated phase 1 data showing an 82% PSA50 rate. The FDA accepted a filing for Ono Pharmaceuticals' tirabrutinib seeking accelerated approval in primary central nervous system lymphoma. Research findings also identified a new kidney cancer biomarker and showed promising results for the TRK inhibitor repotrectinib and the breast cancer triple therapy gedatolisib plus palbociclib and fulvestrant.

Racial Disparities Persist Across Cancer Incidence and Clinical Trial Outcomes

Two JAMA Network Open studies highlight persistent racial disparities in cancer. One found early-onset cancer rates declining in men but rising in women, with significant variation by race across cancer types. A separate analysis of ovarian cancer trials showed Black patients had lower overall survival and were underrepresented in clinical research.

Novel CAR-T Approaches Show Promise Against Solid Tumors in Preclinical Studies

Two innovative CAR-T approaches show promise against solid tumors in preclinical studies. An in vivo gene editing system generates CAR-T cells directly in the body, while HLA-independent T cell receptors target CD70 across various tumor types. Both methods have demonstrated tumor clearance in mouse models, potentially expanding cell therapy applications beyond blood cancers.

Cryoablation System Shows 83.9% Recurrence-Free Rate in Kidney Cancer Trial

The ProSense Cryoablation System achieved an 83.9% recurrence-free rate in kidney cancer patients after 4 years in the ICESECRET trial. The system treats small renal masses up to 5 cm and is approved in multiple global markets. Detailed results will be presented at the European Conference on Interventional Oncology in April 2026.

Related Clinical Trials

NCT ID Title Status Phase
NCT07410676

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

 RECRUITING PHASE1/PHASE2
NCT07401875

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

 RECRUITING PHASE1
NCT07397611

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

 RECRUITING PHASE2
NCT07327489

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

 RECRUITING
NCT07297160

CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors

 NOT_YET_RECRUITING PHASE1
NCT07284953

A Novel Haemostatic Agent for Robotic Partial Nephrectomy

 WITHDRAWN NA
NCT07243067

Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer

 NOT_YET_RECRUITING
NCT07123090

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

 RECRUITING PHASE2
NCT07065825

Tumor Rupture During Robotic Partial Nephrectomy

 NOT_YET_RECRUITING
NCT06965192

Designing Visual Tools to Enhance Cancer Surgeon Decision-making

 RECRUITING NA